July 30, 2018
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Revised Medical Practice Guidelines 2018 for Healthcare Professionals
newly includes anti-cancer agent TREAKISYM®, as standard-of-care therapy
TOKYO, Japan, July 30, 2018 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”)
announced today that anti-cancer agent, TREAKISYM® (non-proprietary name: bendamustinehydrochloride), has been newly included as a standard-of-care option in the Guidelines for Tumors ofHematopoietic and Lymphoid Tissues 2018 ("Guidelines") issued by JSH (Japan Society ofHematology) on July 20, 2018.
The Guidelines, which are a major revision since the 2013 edition, have been significantly revised toreflect recent dramatic advances in new treatment methods for hematopoietic tumors based onevidence accumulated by experts in hematopoietic oncology practice. Under the Guidelines,TREAKISYM® now covers mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed
refractory low-grade B-cell non-Hodgkin's lymphoma (relapsed refractory low-grade NHL), and has
been newly included as a first-line treatment option for patients with low-grade NHL.
The inclusion of TREAKISYM® in the Guidelines for all approved indications establishes its position,
both in reputation and practice, as a standard treatment for malignant lymphoma. It is expected toreplace conventional standard therapies and to increase its penetration in the market.
In the field of first-line low-grade NHL, approved in December 2016, TREAKISYM®（BR Therapy）
has achieved fifty percent (50%) market share in less than a year and is steadily replacing R-CHOP
as the conventional standard therapy.
By further promoting the appropriate use of TREAKISYM® in the treatment of malignant lymphoma,
SymBio shall continue to develop its business to enhance its corporate value by making further
contributions to patients and healthcare settings.

[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

1About TREAKISYM®
TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug firstused in Germany in the 1970s, is now widely used in more than 50 countries with indications for lowgrade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.
TREAKISYM® Intravenous Infusion 100 mg was approved in October, 2010 for manufacturingand marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma
and mantle cell lymphoma in Japan.

TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia inJapan in August, 2016.

TREAKISYM® Intravenous Infusion 25 mg, a standard low-dose product, was approved formanufacturing and marketing in Japan in September, 2016.

TREAKISYM® was approved for the additional indication of first-line treatment of low-grade Bcell non-Hodgkin’s lymphoma and mantle cell lymphoma in Japan in December, 2016.

TREAKISYM® is currently under Phase 3 clinical study for indication of diffuse large B celllymphoma and accumulating cases.

TREAKISYM® has been marketed by SymBio through its partnership with Eisai Co., Ltd. sinceDecember, 2010.
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who
previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen
Japan. In May, 2016 SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma
USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio’s
underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading
global specialty biopharmaceutical company dedicated to addressing underserved medical needs withmain therapeutic focus in oncology, hematology and pain management.

2